Virtual Challenging Case Clinic: Multiple Myeloma
- Engage with leading experts to strategize on therapeutic options for your patients
- Stay up to date on novel agents approved for the treatment of multiple myeloma, and assess recommended sequencing of therapy


Course Director
Sagar Lonial, MD, FACP
Chief Medical Officer
Professor and Chair, Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Winship Cancer Institute of Emory University
Atlanta, Georgia
Agenda
- Welcome, Introductions, and Pre-session Survey
- General Disease State and Treatment Guidelines
- Expert Insights: Faculty-submitted cases
- Case Presentation, Polling Questions, and Discussion
- Q&A
- Conclusion and Post-session Survey
Upcoming Webinars
JULY 20, 2022
Columbia University l New York, New York
SEPTEMBER 21, 2022
Icahn School of Medicine at Mount Sinai l New York, New York
MARCH 15, 2023
Krina Patel, MD, MSc
UT MD Anderson l Houston, Texas
Broadcast March 15, 2023
Updates from ASH
Peter Voorhees, MD
Atrium Health | Charlotte, North Carolina
MM-associated AL Amyloidosis
Shaji Kumar, MD
Mayo Clinic | Rochester, Minnesota
Broadcast: March 2, 2022Updates from ASH
Krina Patel, MD, MSc
The University of Texas MD Anderson Cancer Center | Houston, Texas
Broadcast: January 19, 2022
Noopur Raje, MD
Massachusetts General Hospital | Boston, Massachusetts
Broadcast: August 18, 2021
Updates from ASCO and EHA
Jonathan Kaufman, MD
Winship Cancer Institute of Emory University | Atlanta, Georgia
Broadcast: June 16, 2021
Nina Shah, MD
UCSF | San Francisco, California
Broadcast on April 21, 2021
This activity is supported by independent educational grants from Bristol-Myers Squibb and Oncopeptides
Recordings From Previous Webinars: 2020 Series
Sagar Lonial, MD, FACP
Winship Cancer Institute of Emory University | Atlanta, Georgia
Broadcast on January 20, 2021
Adam Cohen, MD
University of Pennsylvania | Philadelphia, Pennsylvania
Broadcast on November 18, 2020
Paul G. Richardson, MD
Dana-Farber Cancer Institute | Boston, Massachusetts
Broadcast on September 16, 2020
Krina Patel, MD, MSc
The University of Texas MD Anderson Cancer Center | Houston, Texas
Broadcast on July 15, 2020
Nina Shah, MD
University of California, San Francisco | San Francisco, California
Broadcast on May 20, 2020
This activity is supported by independent educational grants from Bristol-Myers Squibb, GlaxoSmithKline LLC, and Oncopeptides
The target audience for this activity is community and academic medical oncologists, hematologists, hematologic oncologists, advanced practitioners (NP/PA/PharmD), and other healthcare providers who treat patients with MM.
- Evaluate best available evidence regarding the treatment of newly diagnosed and relapsed/refractory MM
- Assess the implications of emerging clinical trial data regarding therapeutic approaches for patients with MM
- Develop strategies to optimize the outcomes of complicated MM cases
As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. All faculty, planners, and others in a position to control continuing education content participating in an accredited continuing education activity are required to disclose all financial relationships with ineligible companies. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating all relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications. All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC or Bio Ascend.
This activity is supported by educational grants from Bristol Myers Squibb and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.